CLNN Valuation

Clene Inc.

Add to Watchlist

Advanced Chart

5.660

+0.32(5.993%)1D

Overview
Forecast
Valuation
Earnings

CLNN Relative Valuation

CLNN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLNN is overvalued; if below, it's undervalued.

Historical Valuation

Clene Inc. (CLNN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 234.83 is considered Overvalued compared with the five-year average of -6.38. The fair price of Clene Inc. (CLNN) is between 1.72 to 2.77 according to relative valuation methord. Compared to the current price of 5.66 USD , Clene Inc. is Overvalued By 104.19%.

Relative Value

Fair Zone

1.72-2.77

Current Price：5.66

104.19%

Overvalued

-2.35

Trailing

Forward

-2.57

EV/EBITDA

Clene Inc.. (CLNN) has a current EV/EBITDA of -2.57. The 5-year average EV/EBITDA is -1.42. The thresholds are as follows: Strongly Undervalued below -3.77, Undervalued between -3.77 and -2.59, Fairly Valued between -0.25 and -2.59, Overvalued between -0.25 and 0.92, and Strongly Overvalued above 0.92. The current Forward EV/EBITDA of -2.57 falls within the Historic Trend Line -Fairly Valued range.

-2.52

EV/EBIT

Clene Inc.. (CLNN) has a current EV/EBIT of -2.52. The 5-year average EV/EBIT is -3.91. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -8.06, Fairly Valued between 0.23 and -8.06, Overvalued between 0.23 and 4.37, and Strongly Overvalued above 4.37. The current Forward EV/EBIT of -2.52 falls within the Historic Trend Line -Fairly Valued range.

234.83

Clene Inc.. (CLNN) has a current PS of 234.83. The 5-year average PS is 441.24. The thresholds are as follows: Strongly Undervalued below -530.29, Undervalued between -530.29 and -44.53, Fairly Valued between 927.01 and -44.53, Overvalued between 927.01 and 1412.78, and Strongly Overvalued above 1412.78. The current Forward PS of 234.83 falls within the Historic Trend Line -Fairly Valued range.

-2.75

P/OCF

Clene Inc.. (CLNN) has a current P/OCF of -2.75. The 5-year average P/OCF is -5.23. The thresholds are as follows: Strongly Undervalued below -17.91, Undervalued between -17.91 and -11.57, Fairly Valued between 1.11 and -11.57, Overvalued between 1.11 and 7.45, and Strongly Overvalued above 7.45. The current Forward P/OCF of -2.75 falls within the Historic Trend Line -Fairly Valued range.

-2.13

P/FCF

Clene Inc.. (CLNN) has a current P/FCF of -2.13. The 5-year average P/FCF is -3.85. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -8.02, Fairly Valued between 0.33 and -8.02, Overvalued between 0.33 and 4.50, and Strongly Overvalued above 4.50. The current Forward P/FCF of -2.13 falls within the Historic Trend Line -Fairly Valued range.

Clene Inc. (CLNN) has a current Price-to-Book (P/B) ratio of -5.91. Compared to its 3-year average P/B ratio of -22.33 , the current P/B ratio is approximately -73.54% higher. Relative to its 5-year average P/B ratio of 54.53, the current P/B ratio is about -110.84% higher. Clene Inc. (CLNN) has a Forward Free Cash Flow (FCF) yield of approximately -31.43%. Compared to its 3-year average FCF yield of -57.29%, the current FCF yield is approximately -45.15% lower. Relative to its 5-year average FCF yield of -41.72% , the current FCF yield is about -24.68% lower.

-5.91

P/B

Median3y

-22.33

Median5y

54.53

-31.43

FCF Yield

Median3y

-57.29

Median5y

-41.72

Competitors Valuation Multiple

The average P/S ratio for CLNN's competitors is 40.28, providing a benchmark for relative valuation. Clene Inc. Corp (CLNN) exhibits a P/S ratio of 234.83, which is 482.97% above the industry average. Given its robust revenue growth of -70.33%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Reviva Pharmaceuticals Holdings Inc

Loss

36.62M

XLO.O

Xilio Therapeutics Inc

CASI Pharmaceuticals Inc

Performance Decomposition

Market capitalization of CLNN increased by 7.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -7.46K to -27.48K.

The secondary factor is the Revenue Growth, contributed -70.33%to the performance.

Overall, the performance of CLNN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-70.33%

91.00K → 27.00K

Revenue Growth

268.53%

-7.46K → -27.48K

Margin Expansion

-190.80%

1.65 → -1.50

P/E Change

7.40%